Reducing the severity of brain blood vessel malformations
Reduction of Brain AVM Severity through Inhibition of Pathogenic Angiogenesis
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10774229
This study is exploring a new way to help people with brain arteriovenous malformations (bAVMs) by using a special treatment that targets a protein linked to these blood vessel issues, with the hope of making the blood vessels safer and reducing the risk of serious problems like bleeding.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10774229 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to treat brain arteriovenous malformations (bAVMs), which are abnormal blood vessel formations in the brain that can lead to severe complications like hemorrhage. The study focuses on inhibiting a protein called vascular endothelial growth factor (VEGF), which is known to contribute to the progression of these malformations. By using a novel agent that binds to VEGF, the research aims to stabilize the abnormal blood vessels and prevent their rupture. This could potentially offer a more effective and less invasive treatment option for patients with bAVMs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with brain arteriovenous malformations who are at risk of rupture.
Not a fit: Patients without brain arteriovenous malformations or those whose condition is not related to VEGF signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of life-threatening hemorrhages in patients with brain arteriovenous malformations.
How similar studies have performed: Previous research has shown promise in targeting VEGF signaling for similar conditions, indicating that this approach may be effective.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SU, HUA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SU, HUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.